Acquired tertiary MET resistance to a combination of selpercatinib and capmatinib in a KIF5B-RET+ NSCLC patient who acquired MET amplification as initial resistance to selpercatinib


Viola W. Zhu, MD PhD1,2, Shannon S. Zhang, MD1, Jian Zhang, PhD3, Jeffrey Swensen, PhD3, Joanne Xiu, PhD3, Sai-Hong Ignatius Ou, MD PhD1,2

Here, we provide an update to our letter to the editor of a patient with KIF5B-RET–positive NSCLC who developed acquired MET amplification after treatment with selpercatinib on expanded access. We switched the patient to cabozantinib, a multitargeted MET and RET tyrosine kinase inhibitor (TKI), at 40 mg once daily together with four cycles of carboplatin, pemetrexed, and bevacizumab combination chemotherapy.

External Link